June 2022 – Get News Story

Blood Cancer Drugs Market Recent Developments, Growth Opportunities Forecast Report 2022-2029 | DataM Intelligence

“Blood Cancer Drugs Market | DataM Intelligence”

Major key companies which are contributing to the growth of the Blood Cancer Drugs Market include Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly. Bristol-Myers Squibb Company, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, UCB SA among others.

Blood Cancer Drugs Market Growth Rate Outlook:

Cancer begins in blood-forming tissue, such as the bone marrow or the immune system’s cells. Examples of blood cancer are leukemia, lymphoma, and multiple myeloma. Also called hematologic cancer. The drugs such as bosulif (bosutinib), bosutinib., busulfan, and busulfex (busulfan) are used in blood cancer treatment.

According to the DataM market research report, the global blood cancer drugs market size was valued at USD billion in 2021, it is projected to reach USD billion by 2029, with growth at a CAGR of % over the forecast period 2022-2029.

Growing awareness among healthcare professionals and patients about the possibility of early diagnosis of cancer and an increase in government funding for research is expected to increase the market growth during the forecast period. Institutes like National Cancer Institute (NCI) receive funds from the U.S. congress to support cancer-related activities.

Market Drivers:

Formulations of novel regulatory approvals for new drugs for blood cancer are expected to drive the growth. For instance, In July 2021, Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).

Moreover, in June 2021, Food and Drug Administration approved avapritinib (Ayvakit, Blueprint Medicines Corp.) for adult patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).

Market Restraints:

Drug approval is a lengthy process of research and regulatory approvals, which can be costly. Almost four phases of clinical trials and various stages of screening with regulatory bodies such as the FDA are involved in the drug approval process.

The costs of failed clinical trials are also high as the clinical trial phases involve huge investments. According to the Tufts Centre for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves is about $2.7 billion. This cost has raised more than 10 folds, with the cost of bringing a new drug to the market being $320 million in the 1990s. Thus, indicating that the high drug approval costs hinder the growth of the blood cancer drugs market.

Market Opportunities:

Most of the companies in the blood cancer drugs market are vigorously investing in technologies such as artificial intelligence (AI) to save time and reduce R&D costs. Artificial intelligence (AI) is the simulation of human intelligence processes by machines, particularly computer systems, with the potential to outperform human intelligence. When compared to human analysis, this technology aids in the study of large quantities of chemical and biological data in order to uncover prospective drug candidates with higher success rates and at a faster speed. By matching blood cancer patients with the most relevant clinical trials, the technology also helps to speed up the patient recruiting process, lowering clinical trial expenditures. For instance, Johnson & Johnson has partnered with BenevolentAI, a UK-based artificial intelligence start-up, to mine data for the development of new oncology drugs.

COVID-19 Impact Analysis:

Due to the coronavirus pandemic many pharmaceutical industries have suspended the clinical trials. In a study, it is estimated that approximately 12,000 clinical trials are going on in the area of cancer. If these trails are stopped or suspended for any reason, it will have a profound impact on the industry. Beyond this, loss of the potential health benefits for patients already enrolled in the trials, the cost of an oncology phase 3 clinical trial is on average at least USD 20 million, which will impose a huge financial hurdle on companies for gaining approval for trial and identification for the patients for the second time. According to, the Centre for Drug Development (UK), the pandemic initially drew recruitment for UK clinical trials to an almost complete pause. From about April 2020 until July or August 2020, all British hospitals stopped recruiting patients into new clinical trials, and they even stopped treating some patients already in clinical trials, if the visits weren’t deemed completely necessary – so clinical development definitely had to pause in the year 2020.

Download Sample Brochure @ https://www.datamintelligence.com/download-sample/blood-cancer-drugs-market

Recent Developments in the Industry:

In May 2021, Natco Pharma has received approval from the US health regulator for generic Lenalidomide capsules indicated for the treatment of adults with multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes. For Lenalidomide capsules in 5 mg, 10 mg, 15 mg, and 25 mg strengths, the company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA)
On March 2, 2021, Amgen announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety, and tolerability of BLINCYTO (blinatumomab) compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) were published in The Journal of the American Medical Association (JAMA).

Market Segmentation:

As per the research analysis, the global blood cancer drugs market is segmented by type into Leukemia, Non-Hodgkin lymphoma, Hodgkin lymphoma, and Myeloma. By drugs type into rituaxan/mabthera (rituximab), gleevac/glivec (imatinib), revlimid (lenalidomide), velcade (bortezomib), tasigna (nilotinib), pomalyst (pomalidomide), vidaza (azacitidine), kyprolis (carfilzomib), adcetris (brentuximab vedotin), others. By route of administration the market is further segmented into oral, parenteral, and others. By end-user into hospitals, clinics, and ambulatory surgical centers.

On the basis of drug type, the rituaxan/mabthera (rituximab) drugs segment is estimated to grow at highest CAGR of % during the forecast period (2022-2029). Mabthera was the first therapeutic monoclonal antibody that targets the CD20 marker on their surface. These cells are central to lot of blood cancers, including common forms of lymphoma and leukemia. It attacks these cells both directly and together with the body’s immune system. Also, in the United States, Europe, and other countries, it is approved for the treatment of adults with the following blood cancers, previously untreated and relapsed/refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and relapsed/refractory chronic lymphocytic leukemia. This drug is also approved for the treatment of adults with auto-immune diseases, severe active rheumatoid arthritis, pemphigus Vulgaris and severe active granulomatosis with polyangiitis and microscopic polyangiitis (GPA/MPA).
Based on type, the non-hodgkin lymphoma segment accounted for the largest market share of around % in 2020 and is expected to grow at a CAGR of % during the forecast period (2022-2029). Non-Hodgkin lymphoma has occupied the second-largest market share. Non-Hodgkin lymphoma is cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. The advances in the diagnosis and treatment of non-Hodgkin’s lymphoma have helped improve the prognosis for people with this disease.

Geographical Classification:

The global blood cancer drugs market is segmented into major countries including North America, Europe, South America, Asia Pacific, the Middle East, and Africa.

North America blood cancer drugs Market:

Awareness of early diagnosis and treatment of cancers, availability of advanced treatment procedures and drugs, advanced healthcare facilities, and financial aid in the U.S. and Canada have contributed to a significant market in the region. There is a large number of drugs approved for the treatment of various kinds of blood cancers in the United States. The list includes both branded and generic drugs that are widely used in combinations.

These market players are also expanding their blood cancer drug business with both organic and inorganic growth strategies. In January 2019, Eli Lilly acquired Loxo Oncology, a U.S.-based manufacturer of target drugs for blood and other cancer treatments. Its proprietary BTK inhibitor Pirtobrutinib (LOXO-305) is under clinical research for blood cancers.

The Asia Pacific is the most lucrative market for blood cancer drugs globally. It is likely to witness a CAGR of % during the forecast period (2021-2028) owing to the rising awareness of chemotherapy and radiation therapy. These cancer treatment procedures use a wide range of therapeutics. China, Australia, India, and Japan are the leading markets for blood cancer drugs in the region owing to a high prevalence rate of leukemia and lymphoma.

Make an Inquire before purchasing the full report @ https://www.datamintelligence.com/enquiry/blood-cancer-drugs-market

Competitive Analysis:

The global blood cancer drug market is highly competitive with the presence of major players. In the collaborations for development, broader product portfolios, and regional expansion in emerging markets are key strategic undertakings of these companies to increase their market share. The market is expected to grow increasingly crowded with several product launches during the forecast period.

Major Companies:

Major key companies which are contributing to the growth of the market include Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly. Bristol-Myers Squibb Company, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, UCB SA among others.

Additional Benefits Post Purchase:

1) Unlimited Analyst support for a period of 1 year.

2) Any query with regards to the scope offered will be addressed within 24- 48 hours.

3) An excel sheet with market numbers will be provided separately.

The Full Report has the below insights:

The report offers a comprehensive evaluation of the market in terms of Market Value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2020-2021), and verifiable projections about market size during the forecast period (2022-2029).
Visualize the composition of the global blood cancer drugs market segmentation by type, drug type, route of administration, end-user, and country highlighting the key commercial assets and players.

By Type: Leukemia, Non-Hodgkin lymphoma, Hodgkin lymphoma, Myeloma
By Drugs Type: Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others
By Route of Administration: Oral, Parenteral, Others
By End User: Hospitals, Clinics, Ambulatory Surgical Centers
By Country: North America, South America, Europe, Asia Pacific and the Middle East and Africa

Identify commercial opportunities in the global blood cancer drugs market by analyzing trends and co-development deals.
The report also covers data insights on various industry forces such as porter’s five forces analysis, supply chain analysis, pricing analysis, regulatory analysis, reimbursement analysis, and unmet needs, etc.
Excel data sheet with thousands of data points of global blood cancer drugs market-level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The report will provide access to approximately 69 market data tables, 68 figures, and close to 200 pages.

Media Contact
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States
Website: https://www.datamintelligence.com/research-report/blood-cancer-drugs-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Blood Cancer Drugs Market Recent Developments, Growth Opportunities Forecast Report 2022-2029 | DataM Intelligence

Affordable Roofing LLC Advises On the Factors to Consider When Choosing a Roofing Company in Kissimmee

Affordable Roofing LLC is a top-rated roofing company in Kissimmee. In a recent update, the agency detailed the factors clients should consider when choosing a roofing contractor.

Kissimmee, FL – June 30, 2022 – In a website post, Affordable Roofing LLC advises on the factors to consider when choosing a roofing company.

The team encouraged clients to do their due diligence to choose contractors who can deliver the best Roofing Kissimmee services. The team pointed out that a roofing company’s reputation determines its reliability and quality of services offered. Positive reviews and testimonials signify a trustworthy company that prioritizes excellence. Property owners can trust the contractors to meet their needs if a company is reputable. Therefore, clients should conduct background research to assess their customer’s experience.

The best Roofer Kissimmee should be licensed and certified to offer residential and commercial roofing services. It means the roofer has met the qualification criteria, handling all aspects of a roofing project. Besides, insurance is critical as it gives property owners optimal peace of mind, knowing they will not be liable for mishaps during the project.

Also, the team pointed out that cost is paramount when choosing a Roofing Installation Contractor Kissimmee. They encouraged clients to set a budget depending on how much they could comfortably spend on the roofing project. They should then choose a moderately priced roofer who does not sacrifice the quality of roofing products and services.

About Affordable Roofing LLC

Affordable Roofing LLC is a top Kissimmee-based company. The company specializes in high-quality services for residential clients. The company offers a wide range of shingle styles and colors and provides lifetime warranties on all projects.

Media Contact
Company Name: Affordable Roofing LLC
Contact Person: Rafael Pereyra
Email: Send Email
Phone: (863) 563-3651
Address:4421 White Oak Cir
City: Kissimmee
State: FL
Country: United States
Website: https://affordableroofingllc.com/

ASCO Power Technologies Drives Power Reliability for Glasgow Wastewater Treatment Plant

• The Glasgow Wastewater Treatment Plant needed a backup power system to maximize uptime.
• A community of over 3,000 people and surrounding ecosystems relied on the plant for sanitation.
• ASCO Power provided a reliable solution needed for continuous power even during extreme conditions.

Florham Park, N.J. – June 30, 2022 – The Glasgow Wastewater Treatment Plant required backup power system improvements to mitigate power interruptions, provide essential sanitation to the community, and protect surrounding ecosystems. The town is nearly a five-hour drive from the nearest metropolitan center, making self-reliance and power reliability a priority. Glasgow’s project engineers turned to ASCO Power Technologies for a robust backup power solution.

ASCO Power’s latest Case Study summarizes how ASCO provided specification development support and solutions for the facility’s backup power challenges. These included approval drawings provided on the same day they were requested and subsequent delivery of rugged critical power products that are easy to select, procure, operate, and own.

ASCO Power provided an 800-Amp SERIES 300 Service Entrance Automatic Transfer Switch as well as a second transfer switch that would be integrated into a low-voltage switchboard from Schneider Electric. This provided the plant with the reliable service needed to maintain power availability even during extreme weather events.

ASCO Power Technologies is proud of its role in helping this mission-critical facility better serve the community that relies on it, which should experience higher power reliability, availability, and peace of mind for years to come. More information about the challenge, the solution, and the outcome is explained in the Glasgow Wastewater Treatment Plant case study.

Read the Case Study here: ASCO Case Study | Wastewater Treatment Plant | Glasgow, Montana, USA

About ASCO Power Technologies

ASCO Power Technologies has provided power reliability solutions for more than 125 years. The firm designs, manufactures, services, and supports automatic transfer switches, power control equipment, load banks, and critical power management appliances. ASCO products serve mission-critical functions in data centers, healthcare facilities, telecommunication networks, commercial buildings, and industrial operations. To learn more about any of ASCO’s premium products and services, call (800) 800 ASCO (2726), email CustomerCare@Ascopower.com, or visit www.ascopower.com. To receive updates on the latest news and updates, follow ASCO on Facebook, Twitter, and LinkedIn.

Media Contact
Company Name: ASCO Power Technologies
Contact Person: Laurence Grodsky
Email: Send Email
Phone: +1 973 307 7352
Address:160 Park Avenue
City: Florham Park
State: New Jersey
Country: United States
Website: https://www.ascopower.com/us/en/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ASCO Power Technologies Drives Power Reliability for Glasgow Wastewater Treatment Plant

Side View Camera System Market Size, Growth, and Analysis Report to 2029 | DataMIntelligence

“DataM Intelligence”

The Global Side View Camera System Market is expected to reach a CAGR of 111.6% during the forecast period (2022-2029).

Market Overview

Factors such expanded traveler vehicle and business vehicle creation, center around further developing eco-friendliness by embracing lightweight innovation, expanded utilization of electrical and electronic parts in vehicles are driving the side view camera framework market.

Download free sample @ https://www.datamintelligence.com/download-sample/side-view-camera-system-market

Market Dynamics

Show part is supposed to be the biggest market during the figure time frameThe presentation part is supposed to be the biggest market during the estimated time frame. The showcase section will hold the biggest market among any remaining parts because of the greater expense of presentations. The side camera framework requires 2 shows and the cost of such shows will continuously outperform the expense of different parts. Expanding speculations and improvements in regards to large-scale manufacturing of excellent Organic Light-Emitting Diode boards set out new plans and open doors for lighting and HMI makers.

For example, in August 2018, Denso Corporation, one of the central parts of the view camera framework market, put USD 270 million in JOLED Inc. JOLED was the primary organization to popularize printed OLED shows. With expanding, reception of cutting-edge show arrangements in the auto business would drive the interest for different presentation types in the side view camera frameworks market during the figure time frame.

Market Segmentation

By Camera Type

Single Camera System
Multi Camera System

By Component

Camera
ECU
Display

By Vehicle Type

Passenger Cars
Commercial Vehicle

By Distribution Channel

OEMs
Aftermarket

View full report @ https://www.datamintelligence.com/research-report/side-view-camera-system-market

Competitive Landscape

The global side view camera system market is consolidated due to the presence of major companies as the technology is still in the developing phase and requires a significant investment. Major companies include Continental AG, Valeo, BMW, Hyundai Mobis, Lexus Samvardhana Motherson, Robert Bosch, Magna International, Stoneridge and Denso Corporation. The major players in the market are known to incorporate numerous market strategies to achieve growth in the global side view camera system market; these include collaborations, acquisitions, product launches, contributions and mergers.

Trending Topics

Automotive Pumps Market

Automotive Steering System Market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Side View Camera System Market Size, Growth, and Analysis Report to 2029 | DataMIntelligence

Neuroendocrine Cancer Market Analysis on Segmentation, Regional and Country Level Forecast Report 2022-2029 | DataM Intelligence

“Neuroendocrine Cancer Market | DataM Intelligence”

Some of the key players which are contributing to the growth of the Neuroendocrine Cancer Market include Amgen, Inc, Bristol-Myers Squibb, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Ipsen Pharmaceuticals, Novartis AG, Pfizer Inc, Hutchinson Medipharma Limited, Tarveda Therapeutics, Progenics Pharmaceuticals, and others.

Neuroendocrine Cancer Market Overview:

The neuroendocrine tumor is a rare tumor that emerges from neuroendocrine cells, which are specialized body cells. It can arise everywhere in the body, although the pancreas, digestive tract, lungs, rectum, and appendix are the most common sites. It is possible for a neuroendocrine tumor to be benign or malignant.

Market Size Growth Rate:

According to the research report published by the DataM Intelligence, the global neuroendocrine cancer market size was valued at USD billion in 2021, it is projected to reach USD billion by 2029, with growth at a CAGR of % over the forecast period 2022-2029.

Increased incidences of neuroendocrine tumors (NETs) are predicted to boost demand for treatment options, boosting the market growth during the forecast period. Novel therapeutics and diagnostic products are being developed rapidly in this field. In addition, the neuroendocrine carcinoma therapy market is predicted to rise rapidly due to joint efforts and endeavors to identify medicines for difficult-to-treat disorders and the rising trend of studying next-generation sequencing techniques.

Market Drivers:

The rising prevalence of neuroendocrine carcinoma, technological improvements, more public awareness, and the expanding number of government initiatives drive market growth. Neuroendocrine tumors are becoming more common worldwide, despite being an uncommon disease. In the United States, more than 12,000 people are diagnosed with neuroendocrine tumors each year. As a result, the rising occurrence of neuroendocrine tumors aids in adopting medications for treating this rare disease.

Market Restraints:

The high cost of developing and treating neuroendocrine cancer is expected to hamper the market growth. A NET ( Neuroendocrine Tumor) treatment can be costly. For patients and their families, costs can cause stress and anxiety. Many people discover that, in addition to treatment expenditures, they have additional, unanticipated expenses associated with their care. Some patients cannot follow or complete their treatment plans due to the high cost of medical care. This may jeopardize their health and result in increased bills in the future.

Download Sample Brochure @ https://www.datamintelligence.com/download-sample/neuroendocrine-cancer-market

Market Opportunities

Drug trials are expected to increase market opportunities in the forecast period to increase research and development. For instance, increasing investments by government organizations is expected to drive market growth. For instance, organizations such as the Neuroendocrine Tumor Research Foundation (NETRF) have invested more than 1.5 USD million in developing advanced radiation therapy called Peptide Receptor Radionuclide Therapy (PRRT).

COVID-19 Impact Analysis

COVID-19 had a slow but steady negative influence on this market, as the pandemic has wreaked havoc on health services for other diseases like cancer, hypertension, diabetes management, and cardiovascular emergencies. The change in healthcare professionals’ attention away from these diseases and toward the COVID-19 criticality has severely influenced the healthcare industry. COIVD-19 significantly impacted life sciences research, as it suspended research activities and slowed the advancement of most research and academic institutes, clinical research facilities, and other organizations. Many research institutes have been redirected to COVID-19 research to tackle the fast-progressing virus.

Recent Developments in the Industry:

On July 30^th, 2018, The US FDA approved Progenics Pharmaceuticals, Inc.’s New Drug Application for AZEDRA (iobenguane I 131) injection for treating patients with pheochromocytoma or paraganglioma who require systemic anticancer therapy.

Market Segmentation:

As per the research analysis, the neuroendocrine cancer market is segmented by therapy type into targeted therapy, somatostatin analogs (SSAs), and others. The market is further segmented by indication into small intestine, lungs, pancreas, gastrointestinal, and others. Based on route of administration the market is segmented into oral and parenteral and by end-user into hospitals, clinics and others.

On the basis of therapy, the somatostatin analogs ( SSAs) segment is estimated to grow at the highest CAGR of %during the forecast period (2022-2029). The therapy segment accounted for the largest market share of the global neuroendocrine cancer market in 2020. Somatostatin analogues are medications that prevent the body from producing excessive amounts of hormones. Some neuroendocrine tumors (NETs) produce high amounts of hormones, resulting in a disease known as carcinoid syndrome. People with carcinoid syndrome may benefit from somatostatin analogues. SSA’s treatment procedure is considered to be safe. Patients resistant to surgery or radiation therapy are frequently treated with SSAs.

Make an Inquire before purchasing the full report @ https://www.datamintelligence.com/enquiry/neuroendocrine-cancer-market

Geographical Classification:

According to the report the market is divided into North America, South America, Europe, Asia-Pacific and Middle East.

North America Neuroendocrine Cancer Market:

North America is found to dominate the market as the United States and Canada have well-structured and developed healthcare systems. Owing to supporting insurance policies in the region, such as Medicare, Medicaid, and Tricare, that facilitate NET treatment. Other factors driving the market include modern healthcare facilities and substantial R&D investment by pharmaceutical companies and regional governments for cancer research.

Asia Pacific Neuroendocrine Cancer Market:

The Asia-Pacific neuroendocrine cancer market size was valued at USD billion in 2021, it is projected to reach at USD billion by 2029, with growth at a CAGR of % over the forecast period 2022-2029.

Competitive Analysis:

The major players are adopting several growth strategies such as acquisitions, product pipeline and collaborations, which are contributing to the growth of the neuroendocrine cancer market globally.

Major Companies:

Some of the key players which are contributing to the growth of the market include Amgen, Inc, Bristol-Myers Squibb, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Ipsen Pharmaceuticals, Novartis AG, Pfizer Inc, Hutchinson Medipharma Limited, Tarveda Therapeutics, Progenics Pharmaceuticals, and others.

Additional Benefits Post Purchase:

1) Unlimited Analyst support for a period of 1 year.

2) Any query with regards to the scope offered will be addressed within 24- 48 hours.

3) An excel sheet with market numbers will be provided separately.

The Full Report has the below insights

The report offers a comprehensive evaluation of the market in terms of Market Value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2020-2021), and verifiable projections about market size during the forecast period (2022-2029).
Visualize the composition of the global neuroendocrine cancer market segmentation by therapy type, indication, route of administration, end-user and region highlighting the key commercial assets and players.

By Therapy Type: Targeted therapy, somatostatin analogs (SSAs) , and others.
By Indication: Small intestine, lungs, pancreas, gastrointestinal and others.
By Route of administration: Oral and parenteral.
By End-user: Hospitals, clinics and others.
By Region: North America, South America, Europe, Asia-Pacific and Middle East

Identify commercial opportunities in the global neuroendocrine cancer market by analyzing trends and co-development deals.
The report also covers data insights on various industry forces such as, porter’s five forces, regulations in each country, pipeline analysis and pricing analysis.
Excel data sheet with thousands of data points global neuroendocrine cancer market-level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The report will provide access to approximately 50+ market data tables, 40+ figures, and close to 180 pages.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuroendocrine Cancer Market Analysis on Segmentation, Regional and Country Level Forecast Report 2022-2029 | DataM Intelligence

iMax Credit Repair Firm Discusses the Services Offered at the Company

iMax Credit Repair Firm is a reputable company helping people improve their credit scores to qualify for loans. In a recent update, the firm highlighted the services it offers to help clients know how they can benefit.

Los Angeles, CA – June 30, 2022 – In a website post, iMax Credit Repair Firm highlighted the services offered by the company. The Los Angeles Credit Repair company helps clients identify the problem and tailor the right services to help them improve their credit scores. The team has extensive experience in general credit repair. This is mainly for individuals who miss out on opportunities because of a bad credit score. They walk the extra yard to help them improve their credit scores for auto loans, credit cards, and housing applications.

The company also specializes in Credit Repair Los Angeles services for business loans. They help entrepreneurs repair negative credit scores to get approved for different business loans. They also help prospective business owners determine the right course of action to secure a loan that best suits their situation. This way, they have the funds they need for successful ventures.

In addition, the company repairs credit scores for clients looking to buy a home, remodel a house, or refinance their homes for better interest rates. The team repairs and builds a client’s credit so that they can have a hassle-free mortgage application process. The company follows a comprehensive approach in every Credit Repair LA service for maximum credit scores. The process involves removing negative credit score items, optimizing the FICO score, and preparing for mortgage loan approvals.

About iMax Credit Repair Firm

iMax Credit Repair Firm is a leading credit repair firm based in Los Angeles, CA. The company follows a systematic process to restore clients’ credits and improve their scores in the shortest time possible.

Media Contact
Company Name: IMax Credit Repair Firm
Contact Person: Ali Akhtar
Email: Send Email
Address:6555 Barton Ave Floor 2
City: Los Angeles
State: CA
Country: United States
Website: https://www.imaxcredit.com/

Pepsico (New York) and Kellogg Co (US) are the Key Players in the Savory Snack Products Market

“MarketsandMarkets™”

The global savory snack products market is estimated to be valued at USD 203.9 billion in 2022 and is projected to reach USD 263.0 billion by 2027 recording a CAGR of 5.2%

The savory snacks products market size is estimated to be valued at USD 203.9 billion in 2022 and is projected to reach USD 263.0 billion by 2027, recording a CAGR of 5.2% during the forecast period in terms of value. The demand for savory snack products is attributed by the significant change in the work culture which is promoting the demand for savory snacks among consumers.

Savory Snack Products Market

Key players in this market include PepsiCO (New York), Kellogg Co (US), General Mills Inc. (US), Calbee (Japan), ITC LIMITED (India), Mondelez International (US), Nestle SA (Switzerland), Grupo Bimbo (Mexico), Hain Celestial (US).

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=182914305

The existing players in the savory snacks products market are fixated upon improving their market shares, while the newer startups are being established rapidly in the savory snacks segment. Savory snacks products can be classified as a fragmented market as it has a large number of organized players at the global level as well as unorganized players present at the local level in several countries. There are numerous existing and emerging companies across the globe.

PepsiCo is an US based company was established in 1965 and is currently one of the leading players operating in the food and beverage specially in savory snack products market with a presence in nearly 200 countries with 22 brands. Some major brands include Lays, Cheetos, Ruffles, Frritos, Doritos, and Walkers. They currently manufacture snacks, such as potato chips, puffs, sticks, corn-based sticks, tortillas, nachos, and beef snacks. It focuses on launching new products in order to gain maximum market share. For instance, in January 2021, PepsiCo announced to launch new Doritos Flamin’ hot cool ranch flavored tortilla chips. These new product launches are increasing the brand visibility of the company across the globe.

Kellogg is one of the leading companies in the breakfast cereals and ready-to-eat snacks industries. The company currently offers products in segments, such as crackers, cookies, savory snacks, toaster pastries, cereal bars, granola bars and bites, fruit-flavored snacks, and convenience foods, including ready-to-eat cereals, frozen waffles, veggie foods, and noodles. Special K, Cheeze-it, and Pringles are some of the popular brands of the company, which contribute majorly to its revenues. Kellogg Company is focusing in expanding their production facilities across the globe. For instance, in November 2019, Kellogg Company announced to expand its existing production facility located in Kunto, Poland. This new expansion is helping the company to increase the production capacity of Pringles, a renowned brand of chips across the globe.

Make an Inquiry @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=182914305

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/savory-snack-products-market-182914305.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pepsico (New York) and Kellogg Co (US) are the Key Players in the Savory Snack Products Market

Polestar Plumbing, Heating & AC Acquires Steve Jones AC in Olathe, KS

Polestar Plumbing, Heating & Air Conditioning is proud to announce the acquisition of Steve Jones Air Conditioning in Olathe, KS. Polestar is a local family-owned and operated business that has served the Kansas City metro region and surrounding areas for 40 years.

Polestar’s emphasis on customer satisfaction, trustworthy service, and fair pricing has established the plumbing and HVAC company as a regional favorite throughout its expanding list of service areas.

With the new addition of the former Steve Jones Air Conditioning in Olathe, KS, Polestar is excited to establish new relationships with even more Kansas and Missouri home and business owners.

Polestar’s new location is located at 26276 Waverly Rd Paola, KS 66071, and will continue to serve customers in nearby Olathe and the surrounding areas.

Steve Jones Air Conditioning was originally founded in 2009 by Mr. Steve Jones and his wife, who served as the majority business owner. By relying heavily on referrals to build their business, the couple was able to maintain a low enough overhead to offer high-quality equipment and services at competitive prices.

Throughout the years, Steve Jones Air Conditioning grew to employ a network of highly trained specialists with the goal of becoming the best Olathe HVAC company.

Former customers of Steve Jones Air Conditioning will be pleased to discover the strikingly similar values embraced by Polestar Plumbing and that Polestar plans to continue Steve Jones Air Conditioning’s tradition of excellence.

With an emphasis on high-quality and friendly service, Polestar exclusively employs NATE & EPA-certified plumbers, each of which has been thoroughly vetted through background checks and drug testing.

Rather than going the route of many national service companies, Polestar has always embraced the company motto, “It’s about the relationship.” As a local family-owned business, Polestar doesn’t consider its customers merely clients, but valued friends, neighbors, and family members.

“This community has shown our business so much support over the years, so ensuring that our clients are well taken care of moving forward is extremely important to me. Polestar truly cares about those that they serve and provide a world-class customer experience. I am excited to be joining the Polestar family and look forward to continuing to serve this great community as Polestar Plumbing, Heating & Air Conditioning.” – Steve Jones, Steve Jones Air Conditioning

Throughout nearly four decades of service, the Polestar family has earned a reputation for excellent service and their tireless work in giving back to the community and those in need. It’s these strong family values that have helped to earn Polestar many HVAC industry awards, including an A+ from the BBB, as well as multiple Lennox awards for training excellence, partner of the year, and the premier dealer award.

Polestar Plumbing plans to offer a wide array of services, including HVAC installation, plumbing, and air conditioner repair in Olathe, KS. The company welcomes inquiries from residential and commercial customers alike.

“We are so proud to be a part of this vibrant community and have loved serving our neighbors here in Kansas City so far. We look forward to continuing to help and serve you in the months and years to come.” – Payton Snell, General Manager, Polestar Plumbing, Heating & Air Conditioning

No matter the service, customers can rest assured that all of Polestar’s work is bonded, licensed, and insured, complete with a 100% satisfaction guarantee.

Each service additionally comes complete with Polestar’s Pristine Property Protection, which utilizes floor savers, floor runners, and a thorough cleanup process to ensure that technicians leave every client’s home or business looking its best.

Polestar looks forward to continuing to provide high-quality AC repair in Olathe, KS, for years to come. New customers are invited to schedule an appointment or explore the exclusive savings offered by Polestar’s membership plan on the Kansas City AC company’s website.

Polestar also offers 24/7 emergency service, which customers can request at any time by calling 913-246-3850.

Media Contact
Company Name: Polestar Plumbing, Heating & Air Conditioning
Contact Person: Jordan Cronin
Email: Send Email
Phone: 913-432-3342
Address:7252 W Frontage Rd
City: Merriam
State: KS 66203
Country: United States
Website: https://www.polestarplumbing.com/

Lost Pablo Picasso Masterpiece Painting Found

Connoisseurs of Picasso artwork, Picasso Today, brings an extraordinary art piece for art lovers once owned by the late kingpin Pablo Escobar.

Los Angeles, California – MUJER DESNUDA is a portal connecting art lovers and collectors to some of Picasso’s extraordinary paintings. They make one masterpiece available for exhibition and ownership at a time. They are bringing Mujer Desnuda Posando, a 1969 Picasso painting, previously owned by the late kingpin Pablo Escobar who was a devoted Picasso collector, to the U.S. The Picasso painting will be on an exhibition tour in the United States this year.

Mujer Desnuda Posando is a masterpiece that connects the two Pablos, opposite poles, through the mutual love for art, and the destiny of fame and money. The two Pablos were both savvy businessmen. Picasso invested in creating the masterpieces, and Escobar invested in art. The painting will soon be up for auction. It will be interesting to see who manages to take it home, the world of the two Pablos.

Pablo Ruiz Picasso (1881-1973) one of the most famous artists in history was a Spanish painter, sculptor and poet. He is considered a co-founder of cubism, a co-inventor of collage, the inventor of constructed sculpture, and the world’s most prolific painter. In a career spanning 78 years, he amassed 300 sculptures, 13,500 paintings, 34,000 illustrations and 100,000 prints and engravings.

“I paint objects as I think them, not as I see them.” – Pablo Picasso

Recently a 1932 Pablo Picasso painting ‘Femme nue couchée,’ was sold for a whopping $67.5 million at Sotheby’s in New York on May 12th, 2022. To view the frenzy of the auction on video: Click Here.

Mujer Desnuda painting has gone through the extensive testing and analysis led by Museum Director Rafael Diaz Chacon, Ph.D of the Museum of Contemporary and Postmodern Art (MACPO) in Bucaramanga, Colombia. The scientific tests performed on the painting are SEM (Scanning Electron Microscope) and X-Ray (stereoradiography and autoradiography) scanning.

Museum Director Rafael Diaz Chacon, Ph.D. evaluating the Picasso

To view a video of the Museum Director’s analysis of the painting: Click Here.

And to view 3D analysis video: Click Here.

A certified analysis of the painting will be available for review to selected members of the art world and news media upon request.

Media Contact
Company Name: Picasso Today
Contact Person: Jose Mauricio Mendoza, MBA
Email: Send Email
Country: United States
Website: https://picassotoday.com/

Gelita AG and NITTA Gelatin, INC. are the major Key Players in the Collagen Market

“MarketsandMarkets™”

The global collagen market size is projected to reach USD 5.3 billion by 2026, recording a CAGR of 5.4%, in terms of value. Collagen has versatile properties that enable it to be extensively used in various industrial applications such as medical, cosmetics, and food & beverages

The global collagen market size is estimated to be valued at USD 4.1 billion in 2021 and is projected to reach USD 5.3 billion by 2026, recording a CAGR of 5.4% during the forecast period in terms of value. The demand for collagen is increasing moderately due to increasing health concerns and rising obesity among consumers.

Collagen Market

Key players in this market include GELITA AG (Germany), NITTA GELATIN, INC. (US), Weishardt Group (France), Darling Ingredients Inc. (US), Nippi Collagen NA Inc. (Japan), Vinh Hoan Corporation (Vietnam), Junca Gelatines S.L. (Spain), Lapi Gelatine S.p.a. (Italy), Gelnex (Brazil), Vital Proteins LLC. (US).

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=220005202

The key players are fixated upon improving their market shares, while their newer start-ups are being established rapidly in the market. The collagen market can be classified as a competitive market as it has the presence of a large number of organized players, accounting for a major part of the market share, present at the global level, as well as unorganized players present at the local level in several countries. There are numerous existing and emerging companies, particularly in the Asian markets.

GELITA AG is one of the leading manufacturers and suppliers of collagen proteins for various applications such as food, health & nutrition, pharmaceutical, specialties & fat, and protein & minerals. It manufactures three major products, namely, gelatin, collagen peptides, and collagen. It offers collagen and collagen peptides used in the production of meat products such as boiling sausage, cooked sausage, and low-fat pastries or ground meat. The company distributes high-quality tailor-made collagens for a wide range of products in food and nutritional supplement industries. The company has more than 18 production plants and sales offices, globally.

Nitta Gelatin, Inc. is a leading producer and supplier of high-quality gelatin, collagen peptides, and collagen proteins. The company is specialized in manufacturing collagen proteins sourced from bovine, porcine, and fish. They offer various types of collagen such as gelatin, native collagen and collagen peptides, which are used in applications such as food & beverage, health care, beauty & wellness, and technical. The company offers collagen peptides for cell cultures and coatings used in the pharmaceutical industry and collagen protein for protein-based food products.

Make an Inquiry @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=220005202

About MarketsandMarkets™

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gelita AG and NITTA Gelatin, INC. are the major Key Players in the Collagen Market